WO2015150921A3 - Methods for treating prostate cancer - Google Patents
Methods for treating prostate cancer Download PDFInfo
- Publication number
- WO2015150921A3 WO2015150921A3 PCT/IB2015/001187 IB2015001187W WO2015150921A3 WO 2015150921 A3 WO2015150921 A3 WO 2015150921A3 IB 2015001187 W IB2015001187 W IB 2015001187W WO 2015150921 A3 WO2015150921 A3 WO 2015150921A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostate cancer
- treating prostate
- subject
- androgen receptor
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Abstract
A method for inhibiting activity of the human androgen receptor in a cell, and a method for treating prostate cancer in a subject in need thereof, using a molecule which specifically inhibits interaction of amino acids 433-438 of the N-terminal domain of the receptor with the RAP74 subunit of TFIIF. A method of inhibiting androgen receptor activity in a cell, and a method for treating prostate cancer in a subject in need thereof, using an inhibitor of the phosphorylation of one or more residues of the N-terminal domain of the androgen receptor selected from the group consisting of: Ser422, Ser424, Ser426, Ser430, Ser431, Ser432, Thr435 and Thr438. A method of diagnosing a subject having, or at risk of having, castration-resistant prostate cancer, comprising determining the phosphorylation status of one or more of residues Ser422, Ser424, Ser426, Ser430, Ser431, Ser432, Thr435 and Thr438.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461974822P | 2014-04-03 | 2014-04-03 | |
US61/974,822 | 2014-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015150921A2 WO2015150921A2 (en) | 2015-10-08 |
WO2015150921A3 true WO2015150921A3 (en) | 2016-03-10 |
Family
ID=53761431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/001187 WO2015150921A2 (en) | 2014-04-03 | 2015-04-03 | Methods for treating prostate cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015150921A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019023654A2 (en) * | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | Discovery of small molecules that target the androgen receptor and uses thereof |
WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | Small molecule modulators of the androgen receptor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054663A1 (en) * | 2003-08-13 | 2005-03-10 | Bennett Christina N. | GSK-3 inhibitors |
WO2006018633A1 (en) * | 2004-08-17 | 2006-02-23 | Imperial Innovations Limited | Use of gsk-3 inhibitors for the treatment of prostate cancer |
-
2015
- 2015-04-03 WO PCT/IB2015/001187 patent/WO2015150921A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054663A1 (en) * | 2003-08-13 | 2005-03-10 | Bennett Christina N. | GSK-3 inhibitors |
WO2006018633A1 (en) * | 2004-08-17 | 2006-02-23 | Imperial Innovations Limited | Use of gsk-3 inhibitors for the treatment of prostate cancer |
Non-Patent Citations (7)
Title |
---|
ALISON J. HOLE ET AL: "Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 3, 20 December 2012 (2012-12-20), US, pages 660 - 670, XP055145617, ISSN: 0022-2623, DOI: 10.1021/jm301495v * |
E. A. MOSTAGHEL ET AL: "Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit", CLINICAL CANCER RESEARCH, vol. 20, no. 4, 15 February 2014 (2014-02-15), US, pages 791 - 798, XP055220529, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-3601 * |
MANUJ TANDON ET AL: "New Pyrazolopyrimidine Inhibitors of Protein Kinase D as Potent Anticancer Agents for Prostate Cancer Cells", PLOS ONE, vol. 8, no. 9, 23 September 2013 (2013-09-23), pages e75601, XP055222794, DOI: 10.1371/journal.pone.0075601 * |
OUMATA N ET AL: "Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 17, 11 September 2008 (2008-09-11), pages 5229 - 5242, XP002544873, ISSN: 0022-2623, [retrieved on 20080813], DOI: 10.1021/JM800109E * |
QING ZHU ET AL: "Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo", PROSTATE., vol. 71, no. 8, 1 June 2011 (2011-06-01), US, pages 835 - 845, XP055222884, ISSN: 0270-4137, DOI: 10.1002/pros.21300 * |
RAYMOND J. ANDERSEN ET AL: "Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor", CANCER CELL, vol. 17, no. 6, 1 June 2010 (2010-06-01), US, pages 535 - 546, XP055223053, ISSN: 1535-6108, DOI: 10.1016/j.ccr.2010.04.027 * |
TIMOTHY C. THOMPSON: "Grappling with the Androgen Receptor: A New Approach for Treating Advanced Prostate Cancer", CANCER CELL, vol. 17, no. 6, 1 June 2010 (2010-06-01), US, pages 525 - 526, XP055220515, ISSN: 1535-6108, DOI: 10.1016/j.ccr.2010.05.018 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015150921A2 (en) | 2015-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3675714A4 (en) | Devices and methods for vascular navigation, assessment and/or diagnosis | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
WO2015157252A8 (en) | Treatment of cancer using anti-cd19 chimeric antigen receptor | |
MX2019011911A (en) | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS. | |
WO2015153514A8 (en) | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists | |
HK1247216A1 (en) | Microbial transglutaminases, substrates therefor and methods for the use thereof | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
EP3451908A4 (en) | Devices and methods for vascular navigation, assessment and/or diagnosis | |
MX2018016057A (en) | Compositions and methods for treating cardiovascular disease. | |
WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
WO2015009740A3 (en) | Anti-mucin 1 binding agents and uses thereof | |
GB201620377D0 (en) | Systems, methods, and kits for cleansing an ocular region | |
WO2016079110A3 (en) | Use of enzyme for cleaning | |
WO2017035176A8 (en) | Method of preventing or treating obesity with an emc10 inhibitor | |
WO2015153948A3 (en) | Microtentacle imaging in patient tumor samples | |
EP3511422A3 (en) | Methods and compositions for diagnosing, prognosing, and treating endometriosis | |
MX2016001439A (en) | Compositions and methods for identifying a risk of cancer in a subject. | |
WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
EP3271485A4 (en) | Methods for diagnosing and treating follicular lymphoma | |
WO2016141334A9 (en) | Compositions and methods for diagnosing and treating autoimmune diseases | |
MX2017013729A (en) | Specific detection of clusterin isoforms. | |
EP3702455A4 (en) | Preparation method for in situ hybridisation probe | |
WO2016167944A8 (en) | Compositions and methods for treating autism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15744338 Country of ref document: EP Kind code of ref document: A2 |